2:26:33

Use of Biomarkers for Diagnosing and Assessing Treatment Response in Noncirrhotic NASH Trials-D2-AM

4:07:45

FDA Clinical Investigator Training Course (CITC) 2024 (Day 3 of 3)

4:38:30

FDA Clinical Investigator Training Course (CITC) 2024 (Day 1 of 3)

59:45

Clinicians Connect: Conversations w/ FDA's CMO on reducing cases of congenital syphilis & syphilis

4:59:26

FDA Clinical Investigator Training Course (CITC) 2024 (Day 2 of 3)

1:57:53

Clinical Pharmacology Considerations for Novel Therapeutic Modalities

1:57:16

M13A: Bioequivalence for Immediate-Release Solid Oral Dosage Forms - Implementing the Final Guidance

50:02

Cannabis Products and the Potential Impact on Patients